Ontology highlight
ABSTRACT:
SUBMITTER: Schneeweiss A
PROVIDER: S-EPMC6153514 | biostudies-literature | 2018 Oct
REPOSITORIES: biostudies-literature
Schneeweiss Andreas A Park-Simon Tjoung-Won TW Albanell Joan J Lassen Ulrik U Cortés Javier J Dieras Veronique V May Marcus M Schindler Christoph C Marmé Frederik F Cejalvo Juan Miguel JM Martinez-Garcia Maria M Gonzalez Iria I Lopez-Martin Jose J Welt Anja A Levy Christelle C Joly Florence F Michielin Francesca F Jacob Wolfgang W Adessi Céline C Moisan Annie A Meneses-Lorente Georgina G Racek Tomas T James Ian I Ceppi Maurizio M Hasmann Max M Weisser Martin M Cervantes Andrés A
Investigational new drugs 20180119 5
Purpose To investigate the safety and clinical activity of comprehensive human epidermal growth factor receptor (HER) family receptor inhibition using lumretuzumab (anti-HER3) and pertuzumab (anti-HER2) in combination with paclitaxel in patients with metastatic breast cancer (MBC). Methods This phase Ib study enrolled 35 MBC patients (first line or higher) with HER3-positive and HER2-low (immunohistochemistry 1+ to 2+ and in-situ hybridization negative) tumors. Patients received lumretuzumab (10 ...[more]